Loading
Pay hospitals a single amount for a whole course of cancer treatment, with extra for following the evidence, rather than paying per visit and per drug, which rewards fragmentation.
The US Oncology Care Model and its successor tested episode-based payment for chemotherapy episodes with quality measures; results on cost were mixed, but process measures improved. A design that ties a larger share of payment to guideline concordance, supportive care access, and avoidance of low-value end-of-life chemotherapy, while adjusting for case mix, could align incentives with coordination. This is a payer experiment, and needs careful attention to unintended effects.
Shares Mortality due to cancer treatment delay: systematic review and meta-analysis, Fragmented care and guideline gaps.
Shares Mortality due to cancer treatment delay: systematic review and meta-analysis, Fragmented care and guideline gaps.
Shares Mortality due to cancer treatment delay: systematic review and meta-analysis, Fragmented care and guideline gaps.
Shares Mortality due to cancer treatment delay: systematic review and meta-analysis, Fragmented care and guideline gaps.
Shares Incentives reward me-too drugs and marginal gains, Fragmented care and guideline gaps, Prices and value.
Shares Mortality due to cancer treatment delay: systematic review and meta-analysis, Fragmented care and guideline gaps.
Shares Mortality due to cancer treatment delay: systematic review and meta-analysis, Fragmented care and guideline gaps.
Shares Mortality due to cancer treatment delay: systematic review and meta-analysis, Fragmented care and guideline gaps.